Building Pillars of Knowledge in Supportive Care: Focus on Neutropenia
Audio/slides with interactive questions. Live Faculty Q&A. Printable PDF also available.
The educational series is intended for nurses, pharmacists, and others with clinical, research, and management interests of neutropenia management.
STATEMENT OF NEED
Studies have shown that 25-40% of treatment-naïve patients develop febrile neutropenia while undergoing treatment with common chemotherapy regimens. Patients with cancer undergoing chemotherapy are already in a vulnerable state of health and given the seriousness of complications associated with febrile neutropenia, diligent monitoring and risk assessment are key aspects of optimal patient care. It is imperative that clinicians stay up to date on risk factors and risk assessment tools for neutropenia. They must also stay current on key clinical practice guidelines for the use of treatments that prevent/reduce the incidence of infection associated with neutropenia.
On completion of this activity, participants should be able to:
- Outline the risk factors for neutropenia in patients with cancer undergoing chemotherapy
- Review advances in the prevention and management of neutropenia, including updated evidence-based guidelines
- Examine approaches for improving patient outcomes by identifying patients at risk and preventing or reducing the incidence of neutropenia
- Introduction (5 minutes)
- Presentation of clinical case study (5 min)
- Discuss risk factors for neutropenia in patients with cancer undergoing chemotherapy (10 min)
- Review recent advances in the management of febrile neutropenia in cancer patients (10 min)
- Approaches for improving patient outcomes (10min)
- “Solve” clinical case study based on evidence and guidelines (15min)
- Evaluation and posttest (5 minutes)
LeAnne Kennedy, PharmD, BCOP
Pharmacy Clinical Coordinator
Hematology and Oncology
Wake Forest Baptist Health
Dr. Kennedy has no financial relationships to disclose relating to the content of this activity.
Kathleen Colson, RN, BSN, BS
Clinical Research Nurse
Dana Farber Cancer Institute
Ms. Colson is a consultant for Merck and Millennium Pharmaceuticals, Inc.
Regina Cunningham, PhD, RN, AOCN
Senior Director Oncology
The Tisch Cancer Institute
Mount Sinai Medical Center
New York, NY
Dr. Cunningham has disclosed that she serves on speakers’ bureau for Merck.
The planners and managers have no financial or other relationship to products or devices with commercial interests related to the content of this CE/CME activity.
To receive a statement of credit, you must:
- Review the full content of the activity
- Complete the questions within the activity
- Complete the evaluation at the end of the activity.
Creative Educational Concepts, Inc. (CEC) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
This knowledge-based activity has been assigned ACPE # 0245-0000-11-017-H01-P and will award 1.0 contact hour (0.10 CEUs) of continuing pharmacy education credit. CEC complies with the Criteria for Quality for continuing education programming.
Creative Educational Concepts, Inc. (CEC) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
CEC provides this activity for 1.0 contact hour.
Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.
Your statement of credit will be issued immediately upon successful completion of the posttest and evaluation form.
This activity is complimentary.
It is the policy of CEC, Astute CE and COE to ensure independence, balance, objectivity, scientific rigor, and integrity in their continuing education activities.
Those involved in the development of this continuing education activity have made all reasonable efforts to ensure that information contained herein is accurate in accordance with the latest available scientific knowledge at the time of accreditation of this continuing education activity. Information regarding drugs (e.g., their administration, dosages, contraindications, adverse reactions, interactions, special warnings, and precautions) and drug delivery systems is subject to change, however, and the reader is advised to check the manufacturer's package insert for information concerning recommended dosage and potential problems or cautions prior to dispensing or administering the drug or using the drug delivery systems.
Fair balance is achieved through ongoing and thorough review of all presentation materials produced by faculty, and all educational and advertising materials produced by supporting organizations, prior to educational offerings. Approval of credit for this continuing education activity does not imply endorsement by CEC for any product or manufacturer identified.
UNLABELED USE DISCLOSURE
This activity may include discussions of products or devices that are not currently approved for use by the Food and Drug Administration (FDA), or are currently investigational.
This activity is jointly sponsored by Creative Educational Concepts, Inc., Center of Excellence Media, LLC, and Astute Continuing Education, LLC.
This activity is supported by an independent educational grant from Amgen, Inc.
REQUIRED COMPUTER HARDWARE/SOFTWARE: